S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:VNDAVanda Pharmaceuticals Stock Price, Forecast & News

$11.02
+0.19 (+1.75 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.74
Now: $11.02
$11.07
50-Day Range
$10.08
MA: $11.18
$12.02
52-Week Range
$7.12
Now: $11.02
$17.85
Volume991,606 shs
Average Volume705,135 shs
Market Capitalization$601.14 million
P/E Ratio5.15
Dividend YieldN/A
Beta0.48
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More
Vanda Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$227.19 million
Cash Flow$2.25 per share
Book Value$7.70 per share

Profitability

Net Income$115.55 million

Miscellaneous

Employees270
Market Cap$601.14 million
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$11.02
+0.19 (+1.75 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

How has Vanda Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VNDA stock has increased by 4.0% and is now trading at $11.02.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Vanda Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Vanda Pharmaceuticals
.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Vanda Pharmaceuticals
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting analysts' consensus estimates of $0.01. The biopharmaceutical company earned $58 million during the quarter, compared to analysts' expectations of $57.53 million. Vanda Pharmaceuticals had a return on equity of 30.60% and a net margin of 49.12%.
View Vanda Pharmaceuticals' earnings history
.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $249.4 million.

What price target have analysts set for VNDA?

4 analysts have issued 12-month price targets for Vanda Pharmaceuticals' stock. Their forecasts range from $12.00 to $25.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $16.00 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts' price targets for Vanda Pharmaceuticals
.

Has Vanda Pharmaceuticals been receiving favorable news coverage?

News headlines about VNDA stock have trended neutral this week, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Vanda Pharmaceuticals
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,910,000 shares, an increase of 18.7% from the June 15th total of 4,980,000 shares. Based on an average trading volume of 743,400 shares, the days-to-cover ratio is currently 7.9 days. Approximately 11.3% of the company's shares are short sold.
View Vanda Pharmaceuticals' Current Options Chain
.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Zogenix (ZGNX), NVIDIA (NVDA), Array Biopharma (ARRY), Micron Technology (MU), Exelixis (EXEL) and ImmunoGen (IMGN).

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the following people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include WINTON GROUP Ltd (1.07%), Assenagon Asset Management S.A. (0.86%), Principal Financial Group Inc. (0.75%), Profit Investment Management LLC (0.35%), Russell Investments Group Ltd. (0.27%) and Swiss National Bank (0.22%). Company insiders that own Vanda Pharmaceuticals stock include Aranthan Jones II, Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams.
View institutional ownership trends for Vanda Pharmaceuticals
.

Which major investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., First Quadrant L P CA, 6 Meridian, Strs Ohio, Principal Financial Group Inc., and Texas Permanent School Fund. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Aranthan Jones II, Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan, and Timothy Williams.
View insider buying and selling activity for Vanda Pharmaceuticals
.

Which major investors are buying Vanda Pharmaceuticals stock?

VNDA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Profit Investment Management LLC, Bessemer Group Inc., Swiss National Bank, UBS Group AG, WINTON GROUP Ltd, Exchange Traded Concepts LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Vanda Pharmaceuticals
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $11.02.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $601.14 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is www.vandapharma.com.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.